Interleukin-6 in multiple myeloma and related plasma cell dyscrasias

Current Opinion in Hematology

Volumn 5, Issue 1, 1998, Pages 42-48

  Treon, Steven P ^a   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GROWTH FACTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

BONE MARROW; CANCER GROWTH; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; HUMAN; MULTIPLE MYELOMA; OSTEOBLAST; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; REVIEW; STROMA CELL;

EID: 0031911838     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199801000-00008     Document Type: Review

References (96)

1. Kawano M, Hirano T, Matsuda T, Taga T: Autocrine generation and essential requirements of BSF-2/IL-6 for human multiple myeloma. Nature 1988, 332:83-85.
2. Zhang XG, Klein B, Bataille R: Interleukin 6 is a potent myeloma cell growth factor in patients with aggressive multiple myeloma. Blood 1989, 74:11-13.
3. Barut BA, Zon LI, Cochran MK, Paul SR, Chauhan D, Mohrbacher A, Fingeroth HJ, Anderson KC: Role of interleukin 6 in the growth of myeloma derived cell lines. Leuk Res 1991, 16:951-959.
4. Anderson KC, Jones RM, Morimoto C, Leavitt P, Barut BA: Response patterns of purified myeloma cells to hematopoetic growth factors. Blood 1989, 73:1915-1924.
5. Zhang XG, Bataille R, Widjenes J: Interleukin 6 dependence of advanced malignant plasma cell dyscrasias. Cancer 1992, 69:1373-1376.
6. Westendorf JJ, Ahmann GJ, Greipp PR, Witzig TE, Lust JA, Jelinek DF: Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia 1996, 10:866-876.
7. Bataille R, Jourdan M, Zhang XG, Klein B: Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscraslas. J Clin Invest 1989, 84:2008-2011.
8. Solary E, Guiguet M, Zeller V, Casanovas RO, Caillot D, Chavanet P, Guy H, Mack G: Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass in multiple myeloma. Am J Hematol 1992, 39:163-171.
9. Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R: Immunoreactive interlaukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood 1995, 85:765-771.
10. Kyrstsonis MC, Dedoussis G, Baxevanis C, Stamatelou M, Maniatis A: Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma. Br J Haematol 1996, 92:420-422.
11. Bataille R, Barlogie B, Yang Z, Rossi JF, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B: Biologic effects of anti-interleukin 6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995, 86:685-691.
12. Klein B, Lu Y, Gaillard JP, Harousseau L, Bataille R: Inhibiting IL-6 in human multiple myeloma. Curr Top Microbiol Immunol 1992, 182:236-243.
13. Fattori E, Della Roccca C, Costa P, Giorgio M, Dente B, Pozzi L, Ciliberto G: Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenlc mice. Blood 1994, 83:2570-2579.
14. Suematsu S, Matsukaka T, Matsuda T, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T: Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin-6 transgenic mice. Proc Natl Acad Sci U S A 1994, 89:232-239.
15. Hilbert DM, Kopf M, Mock BA, Kohler G, Rudikoff S: Interleukin-6 is essential for the in vivo development of B lineage neoplasms. J Exp Med 1995, 182:243-248.
16. Romanova L, Alexandrov IA, Schwab G, Hilbert DM, Mushinski JF, Nordan RP: Mechanism of apoptosis suppression of phorbol ester in IL-6 starved murine plasmacytomas: role of PKC modulation and cell cycle. Biochemistry 1996, 35:9900-9906.
17. Lichenstein A, Tu Y, Fady C, Vescio R, Berenson J: Interleukin 6 inhibits apoptosls of malignant plasma cells. Cell Immunol 1995, 162:248-255.
18. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J: Interleukin 6 prevents dexamethasone induced myeloma cell death. Blood 1994, 84:3063-3070.
19. Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M, Kufe DW, Anderson KC: Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997, 89:227-234. This study shows that thanatophoric signals induced by Fas receptor signaling in MM cells are also inhibited by interleukin-6.
20. Chauhan D, Pandey P, Ogata A, Teoh G, Treon S, Urashima M, Kharbanda S, Anderson KC: Dexamethasone Induces apoptosls of multiple myeloma cells in a JNK/SAP kinase Independent mechanism. Oncogene 1997, 15:837-843.
21. Schwarze MM, Hawley RG: Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL. Cancer Res 1995, 55:2262-2265.
22. Bataille R, Chappard D, Klein B: Mechanisms of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 1992, 6:285-295.
23. Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y, Yamaguchi A, Yoshiki S, Matsuda T, Hirano T, et al.: IL-6 is produced by osteoblasts and Induces bone resorption. J Immunol 1990, 145:3297-3303.
24. Nieken J, Mulder NH, Buter J, Vellena E, Limburg PC, Piers DA, de Vries EG: Recombinant human IL-6 induces a rapid and reversible anemia in cancer patients. Blood 1995, 86:900-905.
25. Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J: Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood 1993, 81:3357-3364.
26. Caligaris-Cappio F, Bergui L, Gregoretti M, Gaidano G, Gaboli M, Schena M, Zallone AZ, Marchisio PC: Role of bone marrow stromal cells in growth of human multiple myeloma. Blood 1991, 77:2688-2693.
27. Klein B, Zhang XG, Jourdan M, Content M, Houssiau F, Aarden L, Piechaczyk M, Bataille R: Paracrlne rather than autocrine regulation of myeloma cell growth and differentiation by interleukin-6. Blood 1989, 73:517-526.
28. Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC: CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 1995, 85:1903-1912.
29. Tong AW, Zhang BQ, Mues G, Solano M, Hanson T, Stone MJ: Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro. Blood 1994, 84:3026-3033.
30. Suzuki A, Takahashi T, Okuno Y, Fukumoto M, Fukui H, Koishihara Y, Ohsugi Y, Ohno Y, Imura H: Estimation of interleukin-6 production by reverse transcriptase-polymerase chain reaction in four myeloma cell lines. Leuk Res 1991, 15:1043-1050.
31. Hitzler JK, Martinez-Valdez H, Bergsagel DB, Minden MD, Messner HA: Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My1 to 7 established from patients with advanced stage of disease. Blood 1991, 78:1996-2004.
32. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC: Adhesion of human myeloma derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993, 82:3712-2720.
33. Lokhorst HM, Lamme T, de Smet M, Klein S, deWeger RA, van Oers R, Bloem AC: Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term marrow cultures. Blood 1994, 84:2269-2277.
34. Barille S, Collette M, Bataille R, Amiot M: Myeloma cells upregulate IL-6 but downregulate osteocalcln production by osteoblastic cells through cell to cell contact. Blood 1995, 86:3151-3159.
35. Teoh G, Anderson KC: Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am 1997, 11:27-42.
36. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto KI, Libermann TA, Anderson KC: Multiple myeloma cell adhesion induced interleukin 6 expression in bone marrow stromal cells involves activation of NF-κβ. Blood 1996, 87:1104-1112.
37. Carter A, Merchav S, Silvan-Draxler I, Tatarsky I: The role of interleukin-1 and tumor necrosis factor alpha in human multiple myeloma. Br J Haematol 1990, 74:424-431.
38. Lu ZY, Bataille R, Poubelle P, Rapp MJ, Harousseau JL, Klein B: An interleukin 1 receptor antagonist blocks the IL-1 induced IL-6 paracrlne production through a prostaglandin E2-related mechanism in multiple myeloma. Stem Cells 1995, 113(suppl2):28-34.
39. Urashima M, Ogata A, Chauhan D, Hatziyanni M, Vidriales MB, Dedera DA, Schlossman RL, Anderson KC: Transforming growth factor-beta 1: Differential effects on multiple myeloma versus normal B cells. Blood 1996, 87:1928-1938.
40. Isshiki H, Akira S, Tanabe O, Nakajima T, Shimamoto T, Hirano T, Kishimoto T: Constitutive and IL-1 inducible factors Interact with the IL-6 responsive element in the IL-6 gene. Mol Cell Biol 1990, 10:2757-2762.
41. Muegge K, Vila M, Gusella GL, Musso T, Herrlich P, Stein B, Durum SK: Interleukin 1 induction of the c-jun promoter. Proc Natl Acad Sci U S A 1993, 90:7054-7058.
42. Akira S, Isshiki H, Sugita T, Tanabe O, Kinoshita S, Nishio Y, Nakajima T, Hirano T, Kishimoto T: A nuclear factor for IL-6 expression (NF-IL-6) is a member of the C/EBP family. EMBO J 1990, 9:1897-1906.
43. Urashima M, Chen BP, Chen S, Pinkus GS, Bronson RT, Dedera DA, Hoshi Y, Teoh G, Ogata A, Treon SP, Chauhan D, Anderson KC: The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 1997, 90:754-765. This very interesting study makes two key points: that human myeloma cells preferentially home to human but not murine bone marrow stroma, and that MM cell adherence to BMSCs in vivo can induce human interleukin-6 secretion.
44. Schalling M, Ekman M, Kaaya EE, Linde A, Bieberfeld P: A role for a new herpesvirus (KHSV) in different forms of Kaposi's sarcoma. Nat Med 1995, 1:707-708.
45. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM: Kaposi's sarcoma associated herpesvirus-lika DNA sequences are present in AIDS related body cavity based lymphomas. N Engl J Med 1995, 332:1186-1189.
46. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, d'Agay MF, Clauvel JP, Raphael M, Degos L: Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995, 86:1276-1280.
47. Nicholas J, Ruvolo VR, Zong J, Ciufo D, Guo HG, Reitz MS, Hayward GS: A single 13-kilobase divergent locus in the Kaposi sarcoma-associated herpesvirus (human herpesvlrus-8) genome contains nine open reading frames that are homologous to or related to cellular proteins. J Virol 1997, 71:1963-1974. This fascinating paper identifies a human interleukin-6 gene homolog, viral interleukin-6 gene, along with other important human homolog gene sequences in the genome of the KSHV.
48. Nicholas J, Ruvolo VR, Bums WH, Sandford G, Wan Xiaoyu, Ciufo DS, Hendrickson SB, Guo HG, Hayward GS, Reitz MS: Kaposi's sarcoma associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nature Med 1997, 3:287-292. A detailed study on the functional activity of the human interleukin-6 protein homolog, viral interleukin-6.
49. Rettig MB, Ma HJ, Vescio RA, Pold M, Schiller G, Belson D, Savage A, Nishikubo C, Wu C, Fraser J, Said JW, Berenson J: Kaposi's sarcomaassociated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 1997, 276:1851-1854. This provocative study suggests a key role for KSHV in the pathogenesis of MM. This study identified KSHV in bone marrow dendritic cells from all patients with MM, and 25% of patients with MGUS, but not from normal individuals.
50. Gaillard JP, Bataille R, Brailly H, Zuber C, Yasukawa K, Attal M, Maruo N, Taga T, Kishimoto T, Klein B: Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol 1993, 23:820-824.
51. Ohtani K, Ninomiya H, Hasegawa Y, Kobayashi T, Kojima H, Nagasawa T, Abe T: Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias. Br J Haematol 1995, 91:116-120.
52. Pulkki K, Pelliniemi TT, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R: Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Br J Haematol 1996, 92:370-374.
53. Kyrtsonis MC, Dedoussis G, Zervas C, Perifanis V, Baxevanis C, Stamatelou M, Maniatis A: Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma. Br J Haematol 1996, 93:398-400.
54. Greipp ER, Leong T, Bennett JM, Gaillard JP, Klein B, Oken MM, Kay NE, Van Ness B, Kyle RA: Plasmablastic myeloma response and survival in phase II clinical trial E9487: an Eastern Cooperative Oncology Group (ECOG) myeloma laboratory study group report [abstract]. Proc Annu Meet Am Soc Clin Oncol 1996, 15:A1390.
55. Papadaki H, Kyriakou D, Foudoulakis A, Makridou F, Alexandrakis M, Eliopoulos GD: Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity. Acta Haematologica 1997, 97:191-195.
56. Diamant M, Hansen MB, Rieneck K, Svenson M, Yasukawa K, Bendtzen K: Differential interleukin-6 (IL-6) responses of three established myeloma cell lines in the presence of soluble human IL-6 receptors. Leukemia Res 1996, 20:291-301. This interesting study suggests that sIL-6R complexed with interleukin-6 is sufficient to induce proliferation of MM cells that lack a cell surface interleukin-6 receptor but possess a functional gp130 transmembrane protein.
57. Taga T, Hibit M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T, Kishimoto T: Interleukln 6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989, 58:573-581.
58. Nishimoto N, Ogata A, Shima Y, Tani Y, Ogawa H, Nakagawa M, Sugiyama H, Yoshizaki K, Kishimoto T: Oncostatin M, leukemia inhibitory factor, and interleukin 6 Induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. J Exp Med 1994, 179:1343-1347.
59. Tani Y, Nishimoto N, Ogata A, Shima Y, Yoshizaki K, Kishimoto T: Gp130 in human myeloma/plasmacytoma. Curr Top Microbiol Immunol 1995, 194:229-233.
60. Molden J, Chang Y, You Y, Moore PS, Goldsmith MA: A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem 1997, 272:19625-19631.
61. Ogata A, Chauhan D, Urashima M, Teoh G, Treon S, Schlossman RL, Anderson KC: Interleukin 6 triggers cell growth via the Ras dependent mitogen activated protein kinase (MAPK) cascade. J Immunol 1997, 159:2212-2221.
62. Ogata A, Chauhan D, Urashima M, Teoh G, Treon S, Anderson KC: Blockade of MAPK cascade signaling in interleukin-6 independent multiple myeloma cells. Clin Cancer Res 1997, 3:1017-1022.
63. Urashima M, Ogata A, Chauhan D, Vidriales MB, Teoh G, Hoshi Y, Schlossman RL, DeCaprio JA, Anderson KC: Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein. Blood 1996, 88:2219-2227.
64. Urashima M, Teoh G, Ogata A, Chauhan D, Treon SP, Hoshi Y, DeCaprio JA, Anderson KC: Role of CDK4 and p16INK4A in interleukin 6 mediated growth of multiple myeloma. Leukemia 1997, in press.
65. Urashima M, Teoh G, Chauhan D, Hoshi Y, Ogata A, Treon SP, Schlossman RL, Anderson KC: Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest Induced by dexamethasone and interferon-γ in multiple myeloma cells. Blood 1997, 90:279-289.
66. Portier M, Lees D, Caron E, Jourdan M, Boiron JM, Bataille R, Klein B: Upregulation of IL-6 receptor gene expression in vitro and in vivo in IL-6 deprived myeloma cells. FEBS Lett 1992, 302:35-38.
67. Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B: Measurement of whole body interleukin 6 production: prediction of the efficacy of anti-IL-6 treatments. Blood 1995, 86:3123-3131.
68. Lu ZY, Brochier J, Wijdenes J, Brailly H, Bataille R, Klein B: High amounts of circulating interleukin 6 in the form of monomeric immune complexes during anti-IL-6 therapy: towards a new methodology for measuring overall cytokine production in humans in vivo. Eur J Immunol 1992, 22:2819-2124.
69. Mihara M, Koishihara Y, Fukui H, Yasukawa K, Ohsugi Y: Murine antihuman IL-6 monoclonal antibody prolongs the half life in circulating blood and thus prolongs the bloactivity of human IL-6 in mice. Immunology 1991, 74:55-59.
70. Julian FA, Klein B, Gautherot E, Brailly H: Pharmacokinetic study of anti-interleukin 6 therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. Blood 1995, 85:917-924.
71. van Zaanen, HCT, Koopmans RP, Aarden LA, Rensink HJAM, Stouthard JML, Warnaar SO, Lokhorst HM, van Oers MHJ: Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest 1996, 98:1441-1448.
72. Tsunernari T, Akamatsu KI, Kaiho SI, Sato K, Tsuchiya A, Koishihara Y, Kishimoto T, Ohsugi Y: Therapeutic potential of humanized anti-interleukin 6 receptor antibody: antitumor activity in xenograft model of multiple myeloma. Anticancer Res 1996, 16:2537-2544.
73. Suzuki H, Yasukawa K, Saito T, Goitsuka R, Hasegawa A, Ohsugi Y, Taga T, Kishimoto T: Anti-human interleukin 6 receptor antibody inhibits human myeloma growth in vivo. Eur J Immunol 1992, 22:1989-1993.
74. Lasfar A, Wietzerbin J, Billard C: Differential regulation of interleukin 6 receptors by interleukin 6 and interferons in multiple myeloma cell lines. Eur J Immunol 1994, 24:124-130.
75. Schwabe M, Brini AT, Bosco MC, Rubboli F, Egawa M, Zhao J, Princier GL, Kung HF: Disruption by interferon-alpha of an autocrlne interleukin 6 growth loop in IL-6 dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta chains. J Clin Invest 1994, 94:2317-2325.
76. Jelinek DF, Aagaard-Tillery KM, Arendt BK, Arora T, Tschumper RC, Westendorf JJ: Differential human multiple myeloma cell line responsiveness to interferon-alpha: analysis of transcription factor activation and interleukin 6 receptor expression. J Clin Invest 1997, 99:447-456.
77. Jernberg-Wiklund H, Pettersson M, Nilsson K: Recombinant interferon-γ inhibits the growth of IL-6-dependent human multiple myeloma cell lines in vitro. Eur J Haematol 1991, 46:231-237.
78. Portier M, Zhang XG, Caron E, Lu ZY, Bataille R, Klein B: Gamma-interferon in multiple myeloma: Inhibition of interleukin 6 dependent myeloma cell growth and downregulation of IL-6 receptor expression in vitro. Blood 1993, 81:3076-3082.
79. Herrmann F, Andreff M, Gruss HJ, Brach MA, Lubbert M, Mertelsmann R: Interleukin 4 inhibits growth of multiple myeloma by suppressing Interleukin 6 expression. Blood 1991, 78:2070-2078.
80. Ogata A, Nishimoto N, Shima Y, Yoshizaki K, Kishimoto T: Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via Interference with interleukin-6 signal transduction. Blood 1994, 84:3040-3048.
81. Chen YH, Desai P, Shiao RT, Lavelle D, Haleem A, Chen J: Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid: synergy through modulation of interleukin-6 autocrine loop at multiple sites. Blood 1996, 87:314-323.
82. Savage AD, Belson DJ, Vescio RA, Lichtenstein AK, Berenson JR: Pamidronate reduces IL-6 production by bone marrow stroma from multiple myeloma patients [abstract]. Blood 1996, 88:105A.
83. James K, Premchand N, Skibinska A, Skibinski G, Nicol M, Mason Jl: IL-6, DHEA and the ageing process. Mech Ageing Develop 1997, 93:15-24.
84. Ishikawa H, Tanaka H, twato K, Tanabe O, Asaoku H, Nobuyoshi M, Yamamoto I, Kawano M, Kuramoto A: Effect of glucocorticoids on the biologic activities of myeloma cells: Inhibition of interleukin beta osteoclast activating factor induced bone resorption. Blood 1990, 75:715-720.
85. Puthier D, Bataille R, Barille S, Mellerin MP, Harousseau JL, Ponzio A, Robillard N, Wijdenes J, Amiot M: Myeloma cell growth arrest, apoptosis, and interleukin 6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone. Blood 1996, 88:4659-4666.
86. Pottratz ST, Bellido T, Mocharia H, Crabb D, Manolaga SC: 17β Estradiol Inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor dependent mechanism. J Clin Invest 1994, 93:944-950.
87. Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dalrymple SA, Murray R, Manolagas SC: Regulation of interleukin 6, osteoclastogenesis, and bone mass by androgens: the role of the androgen receptor. J Clin Invest 1995, 95:2886-2895.
88. Yao A, MacLeod SL, Barlogie B, Hardin JW: Multiple myeloma cells contain functional estrogen receptors (ER) mediating suppression of IL-6 but not of cell growth [abstract]. Blood 1995, 86:64A.
89. Jarvinen LS, Pyrhonen S, Kairemo KJA, Paavonen T: The effect of antioestrogens on cytokine production in vitro. Scand J Immunol 1996, 44:15-20.
90. Lust JA, Donovan KA: Novel therapeutic strategies. Cancer Res Therapy Control 1997, in press.
91. Savino R, Ciapponi L, Lahm A, Demartis A, Cabibbo A, Toniatti C, Delmastro P, Altamura S, Ciliberto G: Rational design of a receptor super-antagonist of human interleukin-6. EMBO J 1994, 13:5863-5870.
92. Ehlers M, de Hon FD, HK Bos, Horsten U, Kurapkat G, Van De Leur HS, Grutzinger J, Wullmer A, Brakenhoff JP, Rose-John S: Combining two mutations of human interleukin-6 that affect gp130 activation results in a potent interleukin-6 receptor antagonist on human myeloma cells. J Biol Chem 1995, 270:8158-8163.
93. Sporeno E, Savino R, Ciapponi L, Paonessa G, Cabibbo A, Lahm A, Pulkki K, Sun RX, Toniatti C, Klein B: Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells. Blood 1996, 87:4510-4519.
94. Siegall CB, Nordan RP, Fitzgerald DJ, Pastan I: Cell specific toxicity of a chimeric protein composed of interleukin 6 and pseudomonas exotoxin (IL6-PE40) on tumor cells. Mol Cell Biol 1990, 10:2443-2447.
95. Kreitman RJ, Siegall CB, Fitzgerald DJP, Epstein J, Barlogie B, Pastan I: Interleukin-6 fused to mutant form of pseudomonas exotoxin kills malignant cells from patients with multiple myeloma. Blood 1992, 79:1775-1780.
96. Chadwick DE, Jamal N, Messner HA, Murphy JR, Minden MD: Differential sensitivity of human myeloma cell lines and bone marrow colony forming cells to a recombinant diphtheria toxin-interleukin-6 fusion protein. Br J Haematol 1993, 85:25-36.